The “Cicada” Variant: COVID’s New Stealth Strain

New Delhi, March 27, 2026: The global health landscape is witnessing the emergence of a new COVID-19 subvariant that has captured the attention of virologists and public health officials alike. Formally designated as BA.3.2, the strain has earned the evocative nickname “Cicada” due to its unusual evolutionary trajectory.+1

As of late March 2026, the Cicada variant has been detected in over 25 U.S. states and at least 23 countries worldwide. While it is not yet the dominant strain globally, its rapid rise in parts of Europe and its distinct genetic profile have placed it under intense scientific scrutiny.

Why the Nickname “Cicada”?

In biology, cicadas are famous for remaining underground in a dormant state for years before emerging suddenly in massive numbers. The BA.3.2 variant follows a similar “stealth” pattern.+1

Unlike most recent variants that descended from the JN.1 lineage (the dominant family of 2024 and 2025), Cicada is an “undead” variant. It evolved from an older branch of the Omicron BA.3 lineage that scientists believed had gone extinct in early 2022. After remaining undetected for nearly two years—likely circulating in a hidden animal reservoir or a small, isolated human population—it resurfaced in South Africa in late 2024 and began its global spread in 2025 and early 2026.+1

A “Hyper-Mutated” Profile

What sets Cicada apart is its staggering number of mutations. Modern genomic sequencing has identified 70 to 75 mutations in its spike protein alone—the “key” the virus uses to enter human cells.

• Immune Evasion: This high level of mutation suggests a significant ability to bypass the “immune memory” created by previous infections or older vaccine formulas.
• Genetic Divergence: Because it is not a direct descendant of the recent JN.1 family, the antibodies many people have developed recently may not recognize BA.3.2 as effectively as they do other circulating strains.

Symptoms and Severity

Current data from the CDC and the World Health Organization (WHO) suggest that while Cicada is highly transmissible, there is no evidence yet that it causes more severe disease than previous Omicron versions.

The symptoms remain largely consistent with other COVID-19 strains, though doctors have noted a few specific trends:

• Primary Symptom: A “severe or scratchy sore throat” is frequently reported as the first sign of infection.
• Common Symptoms: Fever, persistent cough, fatigue, and muscle aches.
• Secondary Symptoms: Some patients report gastrointestinal issues, including nausea or diarrhea, and the classic loss of taste or smell is still occasionally present.

Vaccine Effectiveness

The 2025–2026 vaccine formulations were largely designed to target the JN.1 and XFG (Stratus) lineages. Early laboratory studies indicate that while these vaccines may have “reduced neutralization” against Cicada—meaning they might not prevent a mild infection—they are still expected to provide robust protection against severe illness, hospitalization, and death.+1

What the Public Should Know

Public health experts emphasize that while the name “Cicada” sounds dramatic, the emergence of such variants is a natural part of the virus’s transition to an endemic state.

Recommended Precautions:

1. Testing: Standard PCR and rapid antigen tests still accurately detect the Cicada variant.
2. Ventilation: Improving indoor airflow remains one of the most effective ways to reduce transmission.
3. Masking: High-quality masks (N95 or KN95) are still recommended for high-risk individuals in crowded indoor settings.

The WHO currently classifies BA.3.2 as a “Variant Under Monitoring” (VUM). This means they are watching it closely but have not yet seen the surge in hospitalizations that would require a shift to “Variant of Concern” status.